Cargando…

Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer

In pancreatic cancer, acquiring a sufficient amount of tumor tissue is an obstacle. The soluble form of PD-L1 (sPD-L1) may have immunosuppressive activity. Here, we evaluated the prognostic implications of sPD-L1 in unresectable pancreatic cancer. We prospectively enrolled 60 patients treated with f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hyunkyung, Bang, Ju-Hee, Nam, Ah-Rong, Eun Park, Ji, Hua Jin, Mei, Bang, Yung-Jue, Oh, Do-Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668419/ https://www.ncbi.nlm.nih.gov/pubmed/31366979 http://dx.doi.org/10.1038/s41598-019-47330-1

Ejemplares similares

The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy
por: Park, Hyunkyung, et al.
Publicado: (2019)

Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology
por: Ha, Hyerim, et al.
Publicado: (2019)

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
por: Ha, Hyerim, et al.
Publicado: (2016)

Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
por: Park, Woochan, et al.
Publicado: (2021)

Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
por: Jin, Mei Hua, et al.
Publicado: (2020)

Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2019)

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
por: Choi, Younak, et al.
Publicado: (2016)

Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2019)

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)

Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy
por: Cho, Kyoung-Min, et al.
Publicado: (2017)

More Accurate Prediction of Metastatic Pancreatic Cancer Patients’ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity
por: Choi, Younak, et al.
Publicado: (2016)

Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer
por: Cho, Kyoung-Min, et al.
Publicado: (2016)

Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2020)

The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy
por: Choi, Younak, et al.
Publicado: (2016)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index
por: Choi, Younak, et al.
Publicado: (2015)

Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study
por: Kim, Jin Won, et al.
Publicado: (2019)

A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma
por: Kim, Dong-Wan, et al.
Publicado: (2014)

Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma
por: Kim, Hyemin, et al.
Publicado: (2021)

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
por: PARK, EUNJU, et al.
Publicado: (2011)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

Adjuvant Chemotherapy in Microsatellite Instability–High Gastric Cancer
por: Kim, Jin Won, et al.
Publicado: (2020)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Complete Remission of Unresectable Colon Cancer after Preoperative Chemotherapy Selected by Adenosine Triphosphate-Based Chemotherapy Response Assay
por: Huh, Jung Wook, et al.
Publicado: (2008)

Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2010)

Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
por: Kiriukova, Mariia, et al.
Publicado: (2020)

Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer
por: Baek, Sun Kyung, et al.
Publicado: (2011)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan
por: Furuse, Junji
Publicado: (2019)

Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer
por: Moningi, Shalini, et al.
Publicado: (2022)

Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer
por: Kwan, Byung Soo, et al.
Publicado: (2023)

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study
por: Lim, Kyu-Hyoung, et al.
Publicado: (2009)

Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients
por: Lee, Dae-Won, et al.
Publicado: (2015)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

Impact of Splenectomy on Thrombocytopenia, Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer
por: Donahue, Timothy R., et al.
Publicado: (2010)

Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy
por: Park, Hyunkyung, et al.
Publicado: (2019)

TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
por: Kim, Jin Won, et al.
Publicado: (2020)

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
por: Lee, Kyung-Hun, et al.
Publicado: (2007)

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
por: Keam, Bhumsuk, et al.
Publicado: (2011)

Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
por: Woo, Sang Myung, et al.
Publicado: (2017)

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_0vanmvonmdmvjp4kkf8p3kb1mj